-transparent.png){kind=logo}
The effects of m-chlorophenylpiperazine (mCPP), a serotonin receptor agonist, on the release of plasma prolactin (PRL), growth hormone (GH), and cortisol in the rhesus monkey were studied. mCPP was administered intravenously at doses of 0.5, 1.5, and 3.0 mg/kg. GH and cortisol were increased significantly at all doses while PRL was significantly increased only following administration of 3.0 mg/kg mCPP. mCPP administration also produced behavioral alterations in each monkey, including sedation, penile erection, and defecation. PRL, GH and behavioral responses to mCPP were completely blocked by pretreatment with the serotonin antagonist metergoline (MTG). However, pretreatment treatment with MTG failed to entirely anagonize the cortisol response to mCPP. These data suggest that mCPP has prominent neuroendocrine and behavioral effects which are mediated, in part, by serotonergic mechanisms.
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
December 1985,
The Journal of clinical endocrinology and metabolism,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
November 1999,
Psychopharmacology,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
March 1991,
Biological psychiatry,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
March 1997,
Psychopharmacology,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
January 1997,
The American journal of psychiatry,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
June 1994,
Psychopharmacology,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
January 1984,
NIDA research monograph,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
April 1982,
NIDA research monograph,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
July 1976,
Life sciences,
J A Aloi, and
T R Insel, and
E A Mueller, and
D L Murphy
September 1996,
Biological psychiatry,
